I asked the question because this would then sum up our recent discussions of any 'competitors'.
From my understanding Givinostat is less effective than CAP and this may be the reason they were left off the competition slide.
I think CAP has benefit to patients of 3.5 years whilst G only 2.3 years.
this could be a good question though for someone to ask ANP about in Sydney tonight.
- Forums
- ASX - By Stock
- PER
- For General Information
For General Information, page-2659
-
- There are more pages in this discussion • 868 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
|
|||||
Last
8.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $72.12M |
Open | High | Low | Value | Volume |
8.0¢ | 8.1¢ | 7.7¢ | $93.21K | 1.183M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 145811 | 8.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.2¢ | 33389 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 145811 | 0.080 |
1 | 100000 | 0.078 |
1 | 10000 | 0.077 |
1 | 30000 | 0.075 |
3 | 137616 | 0.074 |
Price($) | Vol. | No. |
---|---|---|
0.082 | 33389 | 1 |
0.084 | 343300 | 4 |
0.085 | 263000 | 1 |
0.086 | 300000 | 1 |
0.087 | 400000 | 1 |
Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |